A new under‑the‑skin version of isatuximab is now approved, giving multiple myeloma patients a much faster and more ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis and ...

An international research team led by the Medical University of Vienna has investigated a new peptide derived from cone snail venom that significantly reduced inflammation-induced pain in an animal ...

The FDA has approved a subcutaneous dose for initiation of lecanemab treatment in adults with Alzheimer’s disease, according ...

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study Patients with ≥1 prior line of therapy were ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Subcutaneous amivantamab-lazertinib demonstrated noninferior ...

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed noninferiority ...